CBS 2019
CBSMD教育中心
中 文

推荐文献

Abstract

Recommended Article

Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association Coronary Artery Calcium Is Associated with Left Ventricular Diastolic Function Independent of Myocardial Ischemia Screening for Atrial Fibrillation With Electrocardiography US Preventive Services Task Force Recommendation Statement Home-Based Cardiac Rehabilitation: A Scientific Statement From the American Association of Cardiovascular and Pulmonary Rehabilitation, the American Heart Association, and the American College of Cardiology Patient Characteristics Associated With Antianginal Medication Escalation and De-Escalation Following Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From the OPEN CTO Registry Incidence, Predictors, and Outcomes of In-Hospital Percutaneous Coronary Intervention Following Coronary Artery Bypass Grafting Disrupting Fellow Education Through Group Texting: WhatsApp in Fellow Education? Dynamic atrioventricular delay programming improves ventricular electrical synchronization as evaluated by 3D vectorcardiography

Review ArticleVolume 70, Issue 17, October 2017, Pages 2171-2185

JOURNAL:J Am Coll Cardiol. Article Link

How Low to Go With Glucose, Cholesterol, and Blood Pressure in Primary Prevention of CVD

Hong KN, Fuster V, Bhatt DL et al. Keywords: cardiovascular disease; diabetes; hyperlipidemia; hypertension; primary prevention

ABSTRACT

Diabetes, hyperlipidemia, and hypertension are modifiable risk factors that predict cardiovascular disease events. The effect of these risk factors on incident cardiovascular disease increases with progressively higher levels of glucose, low-density lipoprotein cholesterol, and blood pressure. The thresholds for initiating treatment of these modifiable risk factors and the optimal goals of risk factor modification are a focus of primary prevention research. Although an aggressive approach is appealing, adverse events may occur, and potential physiological barriers may exist. This paper discusses primary prevention of coronary heart disease that may be achieved through modification of diabetes, hyperlipidemia, and hypertension by summarizing current guidelines and pertinent clinical trial data from intervention trials that included a primary prevention cohort.